The way Ocrevus (ocrelizumab) affects immune cell profiles of people with multiple sclerosis (MS) varies depending on what treatments they were on previously, a new study shows.
Understanding these differences could help to optimize treatment approaches for MS patients considering Ocrevus, scientists say.
The study, “Previous disease-modifying treatments influence T lymphocyte kinetics in people with multiple sclerosis switching to ocrelizumab,” was published in the Journal of Neuroimmunology.
